Aligos Therapeutics, Inc. (ALGS) is a South San Francisco–based clinical-stage biopharmaceutical company developing therapies for chronic hepatitis B, hepatitis D and other liver and viral diseases. Its lead asset, pevifoscorvir sodium, is in a Phase 2 trial, and the company has no approved products or product revenue. Shares fell 21.90% on Monday to $1.64, down from Friday's close of $2.10, putting the stock at its lowest level in more than a year. The direction is unambiguously negative. No new company release, filing or analyst action explained the session's decline; the selling extends a repricing that began with the third-quarter update on Nov. 6.
No verified news or fundamental catalyst found for Monday's session specifically. The move is best understood as a continuation of the post-earnings unwind rather than a reaction to a new disclosure. The pattern is consistent with a micro-cap under sustained distribution: the stock has fallen in five of the last seven sessions, has lost about 67% since its Nov. 5 close of $5.02, and is trading below both its 50-day and 200-day moving averages by a wide margin. With a market value under $20 million and a thin order book, modest sell orders can move the price by double digits — over the past 68 sessions the shares have averaged an absolute daily move of 4.6%, and Monday's 21.9% decline was roughly 4.8 times that typical range.
The fundamental break came on Nov. 6, when Aligos reported third-quarter results and disclosed substantial doubt about its ability to continue as a going concern. Cash, equivalents and investments stood at $31.1 million at Sept. 30, down from $77.8 million at the end of 2025, and management said the balance would fund planned operations only into the first quarter of 2027. Quarterly revenue of $2.87 million missed consensus by close to $2 million, even as the per-share loss of $2.09 came in narrower than expected on lower research spending. For a pre-revenue issuer, a going-concern flag is among the most consequential disclosures possible: it signals that the current plan cannot be executed without capital that is not yet secured.
The timeline is the crux of the bear case. Aligos completed enrollment in the Phase 2 B-SUPREME study of pevifoscorvir sodium — 131 patients in the HBeAg-positive cohort and 114 in the HBeAg-negative cohort — but topline data are not expected until late in the third quarter of 2027. That is at least two quarters beyond the projected end of the company's funded runway, leaving a gap that the market assumes will be closed with equity. The company's $150 million at-the-market program and existing shelf registration give it capacity to issue shares at prices now a fraction of where they traded in the summer, which is precisely the dilution overhang weighing on the stock. Offsets exist but are modest in scale: partner Amoytop's $25 million upfront payment for Greater China rights, up to $420 million in potential milestones, and a funded Phase 1 program in China for ALG-170675.
Macro conditions have made the funding question harder. A hotter-than-expected October inflation reading earlier this month pushed market expectations toward a December rate increase, an unusual and particularly hostile backdrop for companies whose valuations rest entirely on cash flows years in the future. Higher discount rates compress the present value of distant clinical milestones and raise the cost of the equity financing Aligos needs, which helps explain why the stock has continued to slide even after the initial earnings shock.
Volume has been running far above normal throughout the decline. On Nov. 11 the stock traded 158,517 shares, nearly four times its 20-day average of roughly 40,000, and turnover stayed heavy on Nov. 12 before thinning on Friday's modest 6% bounce. Monday's early activity was light, consistent with a low-liquidity tape where price gaps rather than orderly trading drive the tape. The selling has been idiosyncratic: it has run opposite a firm broader market, with the Nasdaq Composite having advanced on sessions when Aligos fell sharply. No sector-wide catalyst is apparent among hepatitis B developers, and no technical support has held — the shares are pressing to fresh 52-week lows after breaking below every widely followed moving average.
The scale runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Aligos sits at 50 out of 100.
The verified news is genuinely material for a company this size: a going-concern disclosure, a revenue miss and a funding gap ahead of its most important readout. But it is now ten days old, so it explains the trend more than the session. The price action was unusual — 4.8 times the 4.6% average absolute daily change of the past 68 sessions, with a move of 22% or more occurring only twice in that span. Moderate fundamental weight plus a clearly abnormal swing lands at the midpoint of the scale.
The central variable is capital. Any announced financing — a public offering, accelerated share sales under the at-the-market program, or a royalty and licensing deal — will be judged on size, price and how far it extends the runway. A non-dilutive partnership would change the narrative; a discounted equity raise likely would not. Operationally, investors will look for the start of the chronic hepatitis B cohort for ALG-170675 in the fourth quarter of 2026, China Phase 1 topline data in mid-2027, and the B-SUPREME readout in late 2027, with the ALG-055009 program still dependent on funding or out-licensing. Fourth-quarter and full-year 2026 results, expected in early 2027, will provide the next hard look at the cash balance. Risks include further dilution, program delays and the possibility that the company must prioritize assets rather than develop them all.
Tickeron's Trending AI Robots page offers a curated view of the automated strategies performing best under current market conditions. Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers are featured in this section at any given time. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the list changes as market conditions shift. Investors looking for systematic approaches to volatile names like this one can review the current lineup and compare methodologies before deciding what fits their own objectives.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +9.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALGS advanced for three days, in 186 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
ALGS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALGS as a result. In 82 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ALGS turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 44 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALGS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ALGS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Seasonality Score of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.797) is normal, around the industry mean (3.586). P/E Ratio (-0.528) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.680) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. ALGS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALGS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology